|
|
|
|
Vol. 59, Issue 5, 1044-1050, May 2001
Institut für Pharmakologie und Klinische Pharmakologie, Heinrich-Heine-Universität Düsseldorf, Germany
| |
Abstract |
|---|
|
|
|---|
Migration and proliferation of vascular smooth muscle cells (SMC) in response to platelet-derived growth factor (PDGF) and other mitogens play an important role in restenosis after coronary angioplasty. Elevation of both cAMP and cGMP has been shown to inhibit SMC mitogenesis. The aim of this study was to examine the antimitogenic actions of organic nitrates and sildenafil and to clarify the role of cyclic nucleotide-dependent protein kinases (PKA, PKG) in this action. Organic nitrates [glycerol trinitrate (GTN), isosorbide 5'-mononitrate (ISMN), pentaerythrityl-tetranitrate (PETN)] and the PDE5 inhibitor sildenafil reduced PDGF-induced DNA synthesis, measured by (3H]thymidine incorporation. GTN, ISMN, and PETN acted synergistically with sildenafil (1 µM) on inhibition of PDGF-induced DNA synthesis, increase of intracellular cyclic nucleotides, and vasodilator-stimulated phosphoprotein phosphorylation. The highly selective PKA inhibitor PKI abolished these actions of sildenafil and organic nitrates, whereas the PKG inhibitors KT5823 and (Rp)-8-pCPT-cGMPS had no effect. In addition, selective activation of PKG without inhibition of PDE3 by the cGMP analog 8-pCPT-cGMP (100 µM) had no antimitogenic effect. The data suggest that 1) organic nitrates and sildenafil exert antimitogenic actions by activation of PKA via inhibition of PDE3, but not by activation of PKG and 2) that antimitogenic effects of organic nitrates are potentiated by sildenafil at therapeutic plasma levels.
| |
Introduction |
|---|
|
|
|---|
Proliferation
of vascular smooth muscle cells (SMC) is a typical event in the
pathogenesis and progression of atherosclerosis (Reines and Ross,
1993
). SMC proliferation also occurs after percutaneous coronary
interventions subsequent to endothelial injury (Ross and Fuster, 1996
)
and is mediated by growth factors. One of these growth factors is
platelet-derived growth factor (PDGF), which initiates mitogenic
signaling by activation of the MAP kinase pathway (Davis et al., 1993
;
Claesson-Welsh, 1994
).
NO, formed endogenously by the endothelium or pharmacologically by
release from organic nitrates, increases the intracellular cGMP
concentration in SMC by stimulation of the soluble guanylate cyclase.
The subsequent elevation of cellular cGMP levels has been associated
with an antimitogenic effect in SMC (Cornwell et al., 1994
; Yu et al.,
1997
). It has been also demonstrated that NO donors and structural
analogs of cGMP inhibit SMC proliferation (Yu et al., 1997
; Cornwell et
al., 1994
). Finally, administration of NO donors or
L-arginine, the substrate of NO synthase, has been shown to
reduce intimal thickening after coronary angioplasty in clinical trials
in men (Lablanche et al., 1997
). Despite these data demonstrating
antimitogenic effects of locally enhanced NO levels, no consistent
antimitogenic action has been reported for organic nitrates (Bult et
al., 2000
). Therefore, a more detailed identification of mechanisms
involved in the antimitogenic action of cGMP is necessary to understand
the mechanism of cell proliferation associated with bioactive NO
generation subsequent to endothelial injury.
Cyclic nucleotides bind to and activate specific cyclic
nucleotide-dependent protein kinases (PKA, PKG). Several studies have demonstrated that agents that stimulate PKA inhibit mitogen-induced phosphorylation of the p42/p44 MAP kinases (ERK-1/2) and DNA synthesis in SMC (Bönisch et al., 1998
; Zucker et al., 1998
). One
possibility to stimulate PKA activity is accumulation of cAMP by
inhibition of its breakdown by phosphodiesterases (PDEs). Selective
inhibitors of the cGMP-inhibited PDE3 have been shown to prevent
mitogenesis of SMC both, in in-vitro and in clinical studies
(Tsuchikane et al., 1999
; Osinski and Schrör, 2000
). Thus,
antiproliferative effects related to an increase in intracellular cGMP
might also involve PKA activation (Cornwell et al., 1994
). Short-acting
nitrates (e.g., GTN) might not elevate cGMP levels long enough to allow sufficient cAMP elevation. In addition, GTN might have a promitogenic effect by generation of oxygen radicals (Bult et al., 2000
).
The aim of this study was to elucidate in more detail the mechanism of
cGMP-dependent antimitogenic action in SMC. Specially, we wanted to
know whether elevation of cGMP exerts an antimitogenic effect by itself
or whether any antimitogenic action is indirect in nature (e.g., by
primary inhibition of PDE3 and subsequent elevation of cAMP). Three
different organic nitrates were used as NO donors: GTN, ISMN, and PETN.
Sildenafil was included as a selective inhibitor of PDE5 (Boolell et
al., 1996
), which inhibits cGMP breakdown, eventually resulting in a
more prolonged action of organic nitrates. Whether or not a highly
selective PDE5 inhibitor, such as sildenafil, suppresses PDGF-induced
mitogenesis of SMC by itself has not been explored.
| |
Materials and Methods |
|---|
|
|
|---|
Cell Culture.
Bovine coronary artery SMC were isolated as
described previously (Zucker et al., 1998
). The cells were cultivated
in 80% Ham's F-12/20% Dulbecco's modified Eagle's medium,
supplemented with 10% fetal calf serum, 100 U/ml penicillin, and 0.1 mg/ml streptomycin. Cells were grown in a humidified atmosphere of 5%
CO2/95% air at 37°C. Cell culture material was
purchased from Life Technologies (Eggenstein, Germany) or
Becton-Dickinson (Heidelberg, Germany).
Determination of DNA Synthesis. SMCs were seeded in 24-well plates with serum-free medium for 3 days. PDE inhibitors (Biomol, Hamburg, Germany) were preincubated for 10 min and the cells then stimulated with 10 ng/ml PDGF, isoform BB (Sigma, Deisenhofen, Germany). When the protein kinase inhibitors KT5823 (Sigma), (Rp)-8-pCPT-cGMPS, and myristoylated protein kinase inhibitor peptide (PKI; Promega, Mannheim, Germany) were used, they were added for another 10 min before addition of GTN, ISMN, PETN (ISIS Chemie, Zwickau, Germany), sildenafil (extracted from Viagra; Pfizer, Karlsruhe, Germany) and the PKG activator 8-pCPT-cGMP (Biolog, Bremen, Germany). After 20 h, [3H]thymidine (0.5 µCi/well; DuPont, Bad Homburg, Germany) was added. At the end of the total incubation period of 24 h, the media were removed and the cells were washed twice with 1 ml ice-cold PBS, 0.3 ml of ice-cold perchloric acid (0.3 M), and again with cold PBS. The cells were solubilized with 0.3 ml NaOH (0.1 M) for 30 min at 37°C. [3H]Thymidine incorporation was measured by liquid scintillation counting. All measurements were done in triplicate.
p42/44 MAP Kinase Phosphorylation. SMCs, kept in serum-free medium as described above, were stimulated with PDGF (10 ng/ml) for 10 min. If indicated, the organic nitrates and sildenafil were added 10 min before the mitogen. The p42/p44 MAP kinase phosphorylation was detected by Western blotting using phospho-specific antibodies (New England Biolabs, Beverly, MA) according to the manufacturer's protocol. Briefly, proteins were harvested into SDS sample buffer [6.25 mM Tris-HCl, pH 6.8, 2% SDS (w/v), 10% glycerol, 50 mM dithiothreitol], separated by SDS-polyacrylamide gel electrophoresis, and transferred to polyvinylidene difluoride membranes (Millipore, Bedford, MA). For immunodetection, membranes were probed with phospho-specific MAP kinase antibodies (1:1000; New England Biolabs) followed by incubation with peroxidase-conjugated secondary antibodies (1:3000; Dianova, Hamburg, Germany). Blots were mounted with amidoblack to control protein loading of the lanes.
VASP Phosphorylation. SMC were harvested after a stimulation period of 10 min with the compound to be studied. In experiments with inhibitors of PKA and PKG, the inhibitors were added 10 min before sildenafil and the organic nitrates. SDS-polyacrylamide gel electrophoresis and the following steps were carried out as described above, the vasodilator-stimulated phosphoprotein (VASP)-antibodies were purchased from Santa Cruz Biotechnology (Heidelberg, Germany). Both, dephospho-VASP (p46) and phospho-VASP (p50), were detected by the antibody. Blots were mounted with amidoblack (BioRad, München, Germany) to control protein loading of the lanes.
PKA Activity.
PKA activity in SMC was determined using a
nonradioactive protein kinase assay kit (Calbiochem, San Diego, CA).
Subconfluent SMC were fasted for 48 h in serum-free medium and
stimulated with forskolin (100 nM, Sigma, Deisenhofen, Germany) for 10 min. When combined with sildenafil (30 µM), the PDE3-inhibitor
trequinsin (30 nM; Biomol) or the nonspecific PDE-inhibitor IBMX (1 mM;
Sigma), forskolin was added after preincubation for 10 min with these compounds. Cells were lysed in 20 mM Tris-HCl, pH 7.5, 5 mM EDTA, 10 mM
EGTA, 0.3%
-mercaptoethanol, 1% phenylmethylsulfonyl fluoride of a
saturated solution in isopropanol and 10 mM Benzamidine, then briefly
sonicated and centrifuged at 12,000g for 3 min at 4°C.
Supernatants were assayed for PKA activity by enzyme-linked immunosorbent assay according to the manufacturer's instructions. PKA
activity was referred to that sensitive to 1.0 µM specific PKA
inhibitor (PKI; Sigma). PKA activity ratio was calculated as described
by Torphy et al. (1982)
.
Intracellular Concentration of Cyclic Nucleotides.
Cells
were seeded in 6-well plates in serum-free medium for 72 h. Then,
the cells were washed twice with 2 ml of a balanced salt solution
containing 130 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl2, 0.8 mM MgCl2, 5.5 mM glucose and 20 mM HEPES, pH
7.3. Organic nitrates and sildenafil were added for 10 min. When
forskolin was combined with sildenafil and/or organic nitrates, these
were incubated for 10 min before forskolin was added for another 10 min. The reaction was stopped by removing the buffer and by addition of
ice-cold ethanol (96%). After the ethanol was evaporated,
intracellular cAMP and cGMP levels were determined by radioimmunoassay
as described previously (Schröder and Schrör, 1993
). All
experiments were carried out in duplicate.
Statistics. Data are mean ± SE of n independent experiments, performed in duplicate or triplicate as indicated. Statistical significance was determined using Tukey's test of means. P < 0.05 was considered significant.
| |
Results |
|---|
|
|
|---|
Effects of Organic Nitrates and Sildenafil on PDGF-Induced DNA
Synthesis.
Cell proliferation is preceded by DNA synthesis, taken
as a measure to determine cell proliferation. Addition of PDGF-BB (10 ng/ml) stimulated DNA synthesis in SMC 7 ± 1-fold above control (n = 24, data not shown). This effect was
concentration-dependently inhibited by sildenafil at 1 to 30 µM (Fig.
1). The basal DNA synthesis under resting
conditions was not affected (data not shown). PETN, ISMN, and GTN
inhibited mitogenesis by 25, 40, and 10%, respectively, at the highest
concentrations studied. However, in combination with 1 µM sildenafil,
which by itself did not inhibit mitogenesis, there was a clear
potentiation of the antimitogenic response. Interestingly, there was an
almost complete inhibition of mitogenesis by the combined
administration of ISMN and PETN with sildenafil (1 µM) but not by
combined administration with the shorter-acting
GTN (Figs. 2 to
4).
|
|
|
|
Effects of Sildenafil and Organic Nitrates on Intracellular Cyclic
Nucleotide Accumulation.
Sildenafil and NO donors have been
reported to increase intracellular cGMP levels in SMC (Jeremy et al.,
1997
; Turko et al., 1999
). We confirmed these findings in bovine
coronary artery SMC with sildenafil (1 µM), ISMN (10 µM), and PETN
(3 µM). ISMN and sildenafil increased intracellular cGMP
concentration synergistically. Forskolin (100 nM), a direct adenylate
cyclase activator, had no effect on cGMP levels (Table
1).
|
Effects of Sildenafil and PDE3-Inhibition on PKA Activity.
To
investigate the effect of sildenafil on PKA, we measured PKA activity
by enzyme-linked immunosorbent assay and calculated the PKA activity
ratio. The PKI (1.0 µM) inhibitable PKA activity was taken as
reference. Forskolin was used to stimulate intracellular cAMP levels.
Both sildenafil and the selective PDE3-inhibitor trequinsin, used to
compare the efficacy of sildenafil-induced PDE3-inhibition, were
combined with forskolin. We found that combination of forskolin with
sildenafil or trequinsin caused a comparable activation of PKA. The
combination of forskolin with the nonselective PDE-inhibitor IBMX
strongly stimulated PKA activity (Fig.
5).
|
Role of PKG on PDGF-Induced DNA Synthesis.
To elucidate the
significance of PKG-stimulation for antimitogenic effects of organic
nitrates and sildenafil, the cGMP analog 8-pCPT-cGMP was used. This
selective PKG activator (Geiger et al., 1992
) did not inhibit SMC
mitogenesis (data not shown). In the same concentrations (10 µM and
100 µM), 8-pCPT-cGMP has no effects on PKA activity and also does not
inhibit PDE3 (Geiger et al., 1992
). To determine whether 8-pCPT-cGMP
actually increased intracellular PKG activity, the 8-pCPT-cGMP-induced
VASP phosphorylation was determined. 8-pCPT-cGMP (10 µM and 100 µM)
caused a phosphorylation-dependent shift from 46 to 50 kDa, indicating
intracellular PKG activation by 8-pCPT-cGMP (Fig.
6).
|
|
Role of PKA on PDGF-Induced DNA Synthesis.
The alternative
possibility to explain the antimitogenic actions is activation of PKA.
In contrast to the PKG inhibitors, the highly selective PKA inhibitor
PKImyr abolished the antimitogenic action of
sildenafil nearly completely (Table 2).
In experiments with ISMN and PETN together with sildenafil (1 µM), a
comparable inhibition of the antimitogenic effect by
PKImyr was observed. PKImyr
itself did not exhibit any effect on either stimulation of DNA
synthesis by PDGF on untreated cells (data not shown).
|
Effects of Sildenafil and Organic Nitrates on PDGF-Induced p42/p44
MAP Kinase Phosphorylation.
One of the central mitogenic signaling
pathways of PDGF and other mitogens is the MAP kinase cascade (Davis et
al., 1993
). After stimulation with PDGF, maximal phosphorylation of the
p42/p44 MAP kinase (ERK1/2) was seen after 10 min (data not shown).
Therefore, this time point was chosen for the experiments with
sildenafil and organic nitrates on the PDGF-induced phosphorylation of
MAP kinase. Preincubation with sildenafil inhibited the phosphorylation of p42/p44 MAP kinase in a concentration-dependent manner (Fig. 8). After preincubation with sildenafil
(1 µM), PETN and ISMN inhibited PDGF-induced p42/p44 MAP kinase
phosphorylation. The selective PKA inhibitor
PKImyr reversed this effect of sildenafil and
organic nitrates (Fig. 8).
|
PKA and/or PKG-Dependent Phosphorylation of VASP.
VASP is
phosphorylated by PKA and/or PKG (Halbrügge et al., 1990
; Makert
et al., 1996
). Therefore, VASP phosphorylation was taken as an
indicator for target protein phosphorylation by cyclic nucleotide-dependent protein kinases. The nitric oxide donors GTN (10 µM), ISMN (10 µM), and PETN (3 µM), as well as sildenafil, caused
a phosphorylation of VASP in SMC. In Western blot analysis, the
phosphorylation resulted in a band-shift from 46 to 50 kDa. Figure
9 shows the phosphorylation of VASP
induced by 1 µM and 30 µM sildenafil and 10 µM ISMN. When the
selective PKG inhibitor (Rp)-8-pCPT-cGMPS was added 10 min
before sildenafil or ISMN, the phosphorylation-dependent shift was
reduced. The same effect was seen when the PKA inhibitor
PKImyr was added before 30 µM sildenafil or
before 10 µM ISMN. Only the combination of
PKImyr and (Rp)-8-pCPT-cGMPS resulted
in a complete inhibition of VASP phosphorylation induced by sildenafil
and ISMN.
|
| |
Discussion |
|---|
|
|
|---|
This study demonstrates that sildenafil causes a significant
antimitogenic effect in SMC. Similar yet somehow smaller responses were
seen with PETN and ISMN. There was a clear potentiation of these
reactions by the combined administration of sildenafil and organic
nitrates; however, this reaction was mediated not by PKG but by PKA.
This suggests that accumulation of cGMP results in primary inhibition
of PDE3 with subsequent stimulation of PKA. A schematic presentation of
this hypothesis, including the interaction of PDEs 3 and 5, cyclic
nucleotides, and their corresponding protein kinases is shown on Fig.
10.
|
Although the inhibition of SMC proliferation by both cyclic
nucleotides, cAMP and cGMP, has been reported before (Cornwell et al.,
1994
; Grosser et al., 1995
), the antimitogenic signaling pathway of
cGMP is a matter of debate. The highly selective PKA inhibitor PKI
almost completely abolished the antimitogenic effects of sildenafil and
NO donors. Unfortunately, selective inhibition of PKG is much more
difficult to obtain than inhibition of PKA. In this study, the PKG
inhibitors KT5823 and the cGMP analog (Rp)-8-pCPT-cGMPS were
used. It has been reported that KT5823 inhibits not only PKG, but also
PKA, and might have additional effects on other enzymes (Wyatt et al.,
1991
; Murad et al., 1993
). To determine whether both PKG inhibitors
permeate the cell membrane and actually inhibit PKG, their influence on
VASP phosphorylation was measured by Western blotting. Although
(Rp)-8-pCPT-cGMPS had no effect on basal VASP
phosphorylation, it inhibited the phosphorylation of VASP by sildenafil
and organic nitrates, and KT5823 stimulated basal VASP phosphorylation
(data not shown). This might account for its poor selectivity for PKG
activation. With the two structurally different PKG inhibitors KT5823
and (Rp)-8-pCPT-cGMPS, no significant inhibition of DNA
synthesis and MAP kinase phosphorylation by sildenafil and organic
nitrates was seen (Figs. 7 and 8). This suggests that the antimitogenic
effect of organic nitrates and sildenafil is PKA-mediated. This
conclusion was supported in experiments using the selective PKG agonist
8-pCPT-cGMP. This cGMP analog phosphorylated VASP at
concentrations
10 µM (Fig. 6), but it did not influence
PDGF-induced DNA synthesis, even at 100 µM.
The results of this study are consistent with the findings of other
authors. Southgate and Newby (1990)
reported that the PKA agonist
8-bromo-cAMP, but not the PKG agonist 8-bromo-cGMP, had antimitogenic
effects in rabbit SMC. In another study, it was demonstrated that
8-bromo-cAMP inhibited SMC proliferation in vivo (Indolfi et al.,
1997
). Cornwell et al. (1994)
demonstrated antimitogenic effects of
elevated cGMP levels by NO donors in rat SMC. As in our study, pCPT
failed to inhibit mitogenesis. Collectively, their results suggest that
PKA activity is stimulated secondary to accumulation of cAMP after
inhibition of its breakdown by PDE3.
To clarify the signal transduction of sildenafil and organic nitrates
in SMC, cyclic nucleotide concentrations were determined. Elevation of
cGMP levels by ISMN, PETN, and sildenafil has been reported previously
(Jeremy et al., 1997
; Turko et al., 1999
) and was confirmed here.
Interestingly, there was also an increase in cAMP concentration by
sildenafil, PETN, and ISMN in the same magnitude as obtained with
selective inhibitors of PDE3 (Osinski and Schrör, 2000
). The
stronger antimitogenic effects of PETN and ISMN compared with GTN might
be explained by a longer-lasting NO delivery and subsequent higher cGMP synthesis.
There was a tendency toward increased forskolin-stimulated PKA activity
by sildenafil to levels similar to those of the selective PDE3
inhibitor trequinsin (Fig. 5). Antiproliferative effects by
inhibition of PDE3 in the same cell system have been shown previously
and were also accompanied by only a small increase in cAMP (Osinski and
Schrör, 2000
) as well as antimitogenic effects of forskolin
(Grosser et al., 1995
) and cAMP (Assender et al., 1992
). Cornwell et
al. (1994)
have also shown increases in cAMP and subsequent PKA
stimulation by PKA-dependent antimitogenic agents. The reason for the
very small increase in global cAMP levels may be an additional activity
of PDE4, representing the second major cAMP metabolizing enzyme in SMC
(Polson and Strada, 1996
; Osinski and Schrör, 2000
).
Metabolization of cAMP by PDE4 might overcome the inhibition of PDE3 in
terms of regulating the total cellular cAMP concentrations. However,
for antimitogenic actions, the local cAMP concentration in the
subcellular compartment regulated by PDE3 might be more important than
the total intracellular cAMP level as shown by experiments using
selective inhibitors of PDE3 and PDE4 (Chini et al., 1997
; Osinski and
Schrör, 2000
).
In rat aortic SMC, somewhat different findings have been reported. As
in our study, Yu et al. (1997)
demonstrated antimitogenic actions of
cGMP-elevating agents. However, suppression of the epidermal growth
factor-induced SMC mitogenesis was not reversed by the PKA inhibitor
3',5'-cyclic monophosphorothioate, Rp isomer (10 µM). On the other hand, KT5823 (10 µM) inhibited the antimitogenic effects of the cGMP-elevating agents (Yu et al., 1997
). These differences might be explained by different species, cell culture conditions, and mitogens used. In addition, 10 µM KT5823 might not be
selective for PKG: IC50 value for PKA inhibition,
4 µM; IC50 for PKG inhibition, 0.2 µM (Kase
et al., 1987
).
In conclusion, this study demonstrates for the first time that
sildenafil suppresses mitogenesis of SMC, that this effect is
synergistic with that of organic nitrates and is mediated via activation of PKA but not PKG. One might speculate that a similar mechanism of activation might also be involved in relaxation of the
corpus cavernosum (Stief et al., 2000
). Sildenafil might also potentiate the actions of other cAMP-elevating agents, including sympathomimetics, eventually resulting in arrhythmias and a fall of
blood pressure (Shah, 1998
; Wallis et al., 1999
). The clinical significance of these findings remains to be determined.
| |
Acknowledgments |
|---|
We are grateful to Erika Lohmann for competent secretarial assistance.
| |
Footnotes |
|---|
Received June 1, 2000; Accepted January 22, 2001
This study was supported by the Forschungsgruppe Herz-Kreislauf e.V., Düsseldorf, Germany.
Send reprint requests to: Dr. Karsten Schrör, Institut für Pharmakologie und Klinische Pharmakologie, Heinrich-Heine-Universität, Moorenstr. 5, 40225 Düsseldorf, Germany. E-mail: kschroer{at}uni-duesseldorf.de
| |
Abbreviations |
|---|
SMC, smooth muscle cells; PDGF, platelet-derived growth factor, isoform BB; MAP mitogen-activated protein, PKA, protein kinase A; PKG, protein kinase G; PDE, phosphodiesterase; GTN, glycerol trinitrate; ISMN, isosorbide 5'-mononitrate; PETN, pentaerythrityl tetranitrate; PKI, myristoylated protein kinase A inhibitor peptide; 8-pCPT-cGMP, 8-(p-chlorophenylthio)-cGMP; (Rp)-8-pCPT-cGMPS, 8-(4-chlorophenylthio)guanosine-3',5'-cyclic monophosphorothioate, Rp isomer; VASP, vasodilator-stimulated phosphoprotein; IBMX, 3-isobutyl-1-methylxanthine.
| |
References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
B. Li, L. Yang, J. Shen, C. Wang, and Z. Jiang The Antiproliferative Effect of Sildenafil on Pulmonary Artery Smooth Muscle Cells Is Mediated via Upregulation of Mitogen-Activated Protein Kinase Phosphatase-1 and Degradation of Extracellular Signal-Regulated Kinase 1/2 Phosphorylation Anesth. Analg., October 1, 2007; 105(4): 1034 - 1041. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Yan, C. L. Miller, and J.-i. Abe Regulation of Phosphodiesterase 3 and Inducible cAMP Early Repressor in the Heart Circ. Res., March 2, 2007; 100(4): 489 - 501. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Murray, H. H. Patel, R. Y. S. Suda, S. Zhang, P. A. Thistlethwaite, J. X.-J. Yuan, and P. A. Insel Expression and activity of cAMP phosphodiesterase isoforms in pulmonary artery smooth muscle cells from patients with pulmonary hypertension: role for PDE1 Am J Physiol Lung Cell Mol Physiol, January 1, 2007; 292(1): L294 - L303. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Hofmann, R. Feil, T. Kleppisch, and J. Schlossmann Function of cGMP-Dependent Protein Kinases as Revealed by Gene Deletion Physiol Rev, January 1, 2006; 86(1): 1 - 23. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Wharton, J. W. Strange, G. M. O. Moller, E. J. Growcott, X. Ren, A. P. Franklyn, S. C. Phillips, and M. R. Wilkins Antiproliferative Effects of Phosphodiesterase Type 5 Inhibition in Human Pulmonary Artery Cells Am. J. Respir. Crit. Care Med., July 1, 2005; 172(1): 105 - 113. [Abstract] [Full Text] [PDF] |
||||
![]() |
T.-L. Hwang, H.-W. Hung, S.-H. Kao, C.-M. Teng, C.-C. Wu, and S. J.-S. Cheng Soluble Guanylyl Cyclase Activator YC-1 Inhibits Human Neutrophil Functions through a cGMP-Independent but cAMP-Dependent Pathway Mol. Pharmacol., December 1, 2003; 64(6): 1419 - 1427. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. B. Pilz and D. E. Casteel Regulation of Gene Expression by Cyclic GMP Circ. Res., November 28, 2003; 93(11): 1034 - 1046. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Munzel, R. Feil, A. Mulsch, S. M. Lohmann, F. Hofmann, and U. Walter Physiology and Pathophysiology of Vascular Signaling Controlled by Cyclic Guanosine 3',5'-Cyclic Monophosphate-Dependent Protein Kinase Circulation, November 4, 2003; 108(18): 2172 - 2183. [Full Text] [PDF] |
||||
![]() |
T. Aizawa, H. Wei, J. M. Miano, J.-i. Abe, B. C. Berk, and C. Yan Role of Phosphodiesterase 3 in NO/cGMP-Mediated Antiinflammatory Effects in Vascular Smooth Muscle Cells Circ. Res., September 5, 2003; 93(5): 406 - 413. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. H. Maurice, D. Palmer, D. G. Tilley, H. A. Dunkerley, S. J. Netherton, D. R. Raymond, H. S. Elbatarny, and S. L. Jimmo Cyclic Nucleotide Phosphodiesterase Activity, Expression, and Targeting in Cells of the Cardiovascular System Mol. Pharmacol., September 1, 2003; 64(3): 533 - 546. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. D. Rybalkin, C. Yan, K. E. Bornfeldt, and J. A. Beavo Cyclic GMP Phosphodiesterases and Regulation of Smooth Muscle Function Circ. Res., August 22, 2003; 93(4): 280 - 291. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. T Gewaltig and G. Kojda Vasoprotection by nitric oxide: mechanisms and therapeutic potential Cardiovasc Res, August 1, 2002; 55(2): 250 - 260. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. D. Rybalkin, I. Rybalkina, J. A. Beavo, and K. E. Bornfeldt Cyclic Nucleotide Phosphodiesterase 1C Promotes Human Arterial Smooth Muscle Cell Proliferation Circ. Res., February 8, 2002; 90(2): 151 - 157. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. D. Rybalkin, I. Rybalkina, J. A. Beavo, and K. E. Bornfeldt Cyclic Nucleotide Phosphodiesterase 1C Promotes Human Arterial Smooth Muscle Cell Proliferation Circ. Res., February 8, 2002; 90(2): 151 - 157. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||